CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In a multicenter, double-blind, placebo-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Limmroth, Volker, Barkhof, Frederik, Desem, Nuket, Diamond, Mark P., Tachas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240428/
https://www.ncbi.nlm.nih.gov/pubmed/25239835
http://dx.doi.org/10.1212/WNL.0000000000000926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240428/
https://www.ncbi.nlm.nih.gov/pubmed/25239835
http://dx.doi.org/10.1212/WNL.0000000000000926

Ejemplares similares